ABIO - Arca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapy

Arca Biopharma (NASDAQ:ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the primary endpoint with statistical significance in a Phase 2b trial. The 160-patient international clinical trial was designed to evaluate two dose regimens of rNAPc2 versus standard of care heparin in patients hospitalized with COVID-19. As for the primary efficacy endpoint, the intention to treat (ITT) population showed a decline of 16.8% (-45.7, 36.8, P=0.41) for the rNAPc2  arm, compared to an 11.2% decline (-36, 34.4, P=0.91) in the Heparin group. The p value between groups stood at 0.47. However, the experimental therapy was well tolerated for both higher and lower doses, the company said.

For further details see:

Arca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapy